1 Min Read
Oct 17 (Reuters) - Ignyta Inc
* Ignyta receives European Medicines Agency prime designation for entrectinib in NTRK fusion-positive solid tumors Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.